SCHEMBL24310812

SCHEMBL24310812

CC(C)CCc1ccccc1-c1nc(NSc2cnn(C)c2)nc(Oc2ccccc2)c1C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309610 0.90 — —
SCHEMBL24310386 0.86 KDM4E (0.30) —
SCHEMBL24310169 0.86 FLT4 (0.31) —
SCHEMBL24309551 0.85 FYN (0.32) —
SCHEMBL24309621 0.85 HTR1A (0.37) —
SCHEMBL24310387 0.83 CTSC (0.35) —
SCHEMBL24309841 0.82 PTK2 (0.34) —
SCHEMBL24310568 0.78 — —
SCHEMBL24310590 0.77 IGF1R (0.31) —
SCHEMBL24310217 0.76 HTR1A (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback